Pacer Advisors, Inc. Arcus Biosciences, Inc. Transaction History
Pacer Advisors, Inc.
- $39 Billion
- Q2 2024
A detailed history of Pacer Advisors, Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 545 shares of RCUS stock, worth $8,801. This represents 0.0% of its overall portfolio holdings.
Number of Shares
545
Previous 1,579
65.48%
Holding current value
$8,801
Previous $29,000
72.41%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RCUS
# of Institutions
207Shares Held
49MCall Options Held
173KPut Options Held
151K-
Black Rock Inc. New York, NY9.76MShares$158 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$84.9 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA4.25MShares$68.6 Million0.65% of portfolio
-
State Street Corp Boston, MA3.06MShares$49.3 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.83MShares$29.6 Million0.08% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.17B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...